{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:35:37Z","timestamp":1789889737759,"version":"4.0.1"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":322,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council Taiwan","doi-asserted-by":"publisher","award":["102-2917-I-564-013"],"award-info":[{"award-number":["102-2917-I-564-013"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1111\/ijcp.12548","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T06:33:11Z","timestamp":1413268391000},"page":"436-443","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis"],"prefix":"10.1155","volume":"69","author":[{"given":"J. C.","family":"Hsu","sequence":"first","affiliation":[{"name":"School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences; College of Medicine, National Cheng Kung University; Tainan City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. H.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences; The University of Arizona College of Pharmacy; Tucson AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Y.","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Population Medicine; Harvard Medical School and Harvard Pilgrim Health Care Institute; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"10.1111\/ijcp.12548-BIB0001|ijcp12548-cit-0001","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11539470-000000000-00000","article-title":"Multi-criteria clinical decision support: a primer on the use of multiple criteria decision making methods to promote evidence-based, patient-centered healthcare","volume":"3","author":"Dolan","year":"2010","journal-title":"Patient"},{"key":"10.1111\/ijcp.12548-BIB0002|ijcp12548-cit-0002","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/pds.3464","article-title":"Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives","volume":"22","author":"Leong","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/ijcp.12548-BIB0003|ijcp12548-cit-0003","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1001\/jama.272.24.1942","article-title":"Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake","volume":"272","author":"NIH Consensus Conference","year":"1994","journal-title":"JAMA"},{"key":"10.1111\/ijcp.12548-BIB0004|ijcp12548-cit-0004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"10.1111\/ijcp.12548-BIB0005|ijcp12548-cit-0005","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1743-6109.2007.00765.x","article-title":"Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey","volume":"5","author":"Mulhall","year":"2008","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12548-BIB0006|ijcp12548-cit-0006","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0090-4295(99)00310-6","article-title":"Indications and early results of sildenafil (Viagra) in erectile dysfunction","volume":"54","author":"Virag","year":"1999","journal-title":"Urology"},{"key":"10.1111\/ijcp.12548-BIB0007|ijcp12548-cit-0007","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-5347(05)67900-1","article-title":"Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study","volume":"163","author":"Johannes","year":"2000","journal-title":"J Urol"},{"key":"10.1111\/ijcp.12548-BIB0008|ijcp12548-cit-0008","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/j.1743-6109.2008.00936.x","article-title":"Sexual function, dysfunction, and sexual distress in a prospective, population-based sample of mid-aged, Australian-born women","volume":"5","author":"Dennerstein","year":"2008","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12548-BIB0009|ijcp12548-cit-0009","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ijcp.12074","article-title":"PDE5 inhibitors: considerations for preference and long-term adherence","volume":"67","author":"Smith","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12548-BIB0010|ijcp12548-cit-0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.ju.0000164463.19239.19","article-title":"Chapter 1: the management of erectile dysfunction: an AUA update","volume":"174","author":"Montague","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/ijcp.12548-BIB0011|ijcp12548-cit-0011","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.eururo.2006.01.028","article-title":"EAU guidelines on erectile dysfunction: an update","volume":"49","author":"Wespes","year":"2006","journal-title":"Eur Urol"},{"key":"10.1111\/ijcp.12548-BIB0012|ijcp12548-cit-0012","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur Urol"},{"key":"10.1111\/ijcp.12548-BIB0013|ijcp12548-cit-0013","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-151-9-200911030-00150","article-title":"Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis","volume":"151","author":"Tsertsvadze","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1111\/ijcp.12548-BIB0014|ijcp12548-cit-0014","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.2174\/138161206778343046","article-title":"Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction","volume":"12","author":"Aversa","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1111\/ijcp.12548-BIB0015|ijcp12548-cit-0015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4111\/kju.2010.51.9.647","article-title":"Efficacy and safety of tadalafil 5 mg administered once daily in Korean Men with erectile dysfunction: a prospective multicenter study","volume":"51","author":"Kang","year":"2010","journal-title":"Korean J Urol"},{"key":"10.1111\/ijcp.12548-BIB0016|ijcp12548-cit-0016","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/j.1743-6109.2008.00935.x","article-title":"Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction","volume":"5","author":"Porst","year":"2008","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12548-BIB0017|ijcp12548-cit-0017","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1743-6109.2005.20360.x","article-title":"Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction","volume":"2","author":"McMahon","year":"2005","journal-title":"J Sex Med"},{"key":"10.1111\/ijcp.12548-BIB0018|ijcp12548-cit-0018","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/ijcp.12200","article-title":"The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician","volume":"67","author":"Jackson","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12548-BIB0019|ijcp12548-cit-0019","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/bmj.318.7184.669","article-title":"Sildenafil (Viagra) is used as a recreational drug in England","volume":"318","author":"Aldridge","year":"1999","journal-title":"BMJ"},{"key":"10.1111\/ijcp.12548-BIB0020|ijcp12548-cit-0020","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(98)00015-4","article-title":"Acute myocardial infarction associated with sildenafil","volume":"352","author":"Feenstra","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12548-BIB0021|ijcp12548-cit-0021","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-132-12-200006200-00002","article-title":"The cost-effectiveness of sildenafil","volume":"132","author":"Smith","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1111\/ijcp.12548-BIB0022|ijcp12548-cit-0022","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1742-1241.2009.02328.x","article-title":"Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks","volume":"64","author":"Jackson","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12548-BIB0023|ijcp12548-cit-0023","unstructured":"A multicenter, open label, to evaluate the efficacy and satisfaction of Patrex \u00ae in men with erectile dysfunction http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00468650?term=NCT00468650&rank=1"},{"key":"10.1111\/ijcp.12548-BIB0024|ijcp12548-cit-0024","unstructured":"A study in erectile dysfunction http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01130532?term=NCT01130532&rank=1"},{"key":"10.1111\/ijcp.12548-BIB0025|ijcp12548-cit-0025","unstructured":"A study in erectile dysfunction http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00833638?term=NCT00833638&rank=1"},{"key":"10.1111\/ijcp.12548-BIB0026|ijcp12548-cit-0026","unstructured":"Study of Vardenafil in patients suffering from erectile dysfunction and metabolic syndrome http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00738400?term=NCT00738400&rank=1"},{"key":"10.1111\/ijcp.12548-BIB0027|ijcp12548-cit-0027","unstructured":"Vardenafil orodispersible tablet (odt) versus placebo in males with erectile dysfunction, 50% of whom are to be 65 years or older http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00655629?term=NCT00655629&rank=1"},{"key":"10.1111\/ijcp.12548-BIB0028|ijcp12548-cit-0028","unstructured":"Vardenafil ODT versus placebo in males with erectile dysfunction http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00631969?term=NCT00631969&rank=1"},{"key":"10.1111\/ijcp.12548-BIB0029|ijcp12548-cit-0029","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2490-5-18","article-title":"Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction","volume":"5","author":"Moore","year":"2005","journal-title":"BMC Urol"},{"key":"10.1111\/ijcp.12548-BIB0030|ijcp12548-cit-0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.ijir.3901395","article-title":"Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations","volume":"18","author":"Berner","year":"2006","journal-title":"Int J Impot Res"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12548-BIB0031|ijcp12548-cit-0031","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/pds.1435","article-title":"A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis","volume":"16","author":"Mussen","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12548-BIB0032|ijcp12548-cit-0032","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/pds.1434","article-title":"A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model","volume":"16","author":"Mussen","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/ijcp.12548-BIB0033|ijcp12548-cit-0033","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1524-4733.2010.00725.x","article-title":"A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group","volume":"13","author":"Guo","year":"2010","journal-title":"Value Health"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12548-BIB0034|ijcp12548-cit-0034","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/pds.1436","article-title":"A quantitative approach to benefit-risk assessment of medicines-part 1: the development of a new model using multi-criteria decision analysis; part 2: the practical application of a new model","volume":"16","author":"Mussen","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/ijcp.12548-BIB0035|ijcp12548-cit-0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005650-200202000-00006","article-title":"Multiattribute and single-attribute utility functions for the health utilities index mark 3 system","volume":"40","author":"Feeny","year":"2002","journal-title":"Med Care"},{"key":"10.1111\/ijcp.12548-BIB0036|ijcp12548-cit-0036","doi-asserted-by":"crossref","DOI":"10.4018\/978-1-60960-091-4.ch007","volume-title":"Group Decision Making: Drawing Out and Reconciling Differences","author":"Saaty","year":"2008"},{"key":"10.1111\/ijcp.12548-BIB0037|ijcp12548-cit-0037","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1472-6963-8-106","article-title":"Relationship between risk information on total colonoscopy and patient preferences for colorectal cancer screening options: analysis using the analytic hierarchy process","volume":"8","author":"Katsumura","year":"2008","journal-title":"BMC Health Serv Res"},{"key":"10.1111\/ijcp.12548-BIB0038|ijcp12548-cit-0038","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00044011-200525020-00002","article-title":"Quality-of-life utility values for erectile function and sildenafil treatment","volume":"25","author":"Smith","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1111\/ijcp.12548-BIB0039|ijcp12548-cit-0039","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12548","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:09:02Z","timestamp":1643350142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12548","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10,14]]},"assertion":[{"value":"2014-10-14","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}